Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

(2020) Qiurong Ruan et al.   INTENSIVE CARE MEDICINE

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

(2020) Roujian Lu et al.   LANCET

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia

(2020) Qun Li et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Review of Current Interventions for COVID-19 Prevention

(2020) Deepak Pradhan et al.   ARCHIVES OF MEDICAL RESEARCH

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

(2020) Xiaohua Chen et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID‐19

(2020) Kei Irie et al.   CTS-Clinical and Translational Science

Strong Social Distancing Measures In The United States Reduced The COVID-19 Growth Rate

(2020) Charles Courtemanche et al.   HEALTH AFFAIRS

COVID-19: towards controlling of a pandemic

(2020) Juliet Bedford et al.   LANCET

First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA

(2020) Isaac Ghinai et al.   LANCET

Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore — January 2–February 29, 2020

(2020) Yixiang Ng et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

(2020) Qingxian Cai et al.   Engineering

COVID-19 vaccine development pipeline gears up

(2020) Asher Mullard   LANCET

Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics

(2020) Ramesh Kandimalla et al.   MOLECULAR NEUROBIOLOGY

Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients

(2020) Lu Li et al.   Drug Design Development and Therapy

The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers

(2020) Denis Malvy et al.   PLoS Neglected Tropical Diseases

Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review

(2020) Parisa Ghasemiyeh et al.   Therapeutics and Clinical Risk Management

SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets

(2020) Jayalakshmi Vallamkondu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Favipiravir as an antiviral agent in COVID-19: same script, different cast?

(2020) Nicolas Dauby   CLINICAL INFECTIOUS DISEASES

Tolerability of favipiravir therapy in critically ill patients with COVID‐19: A report of four cases

(2020) Nicolas Dauby et al.   JOURNAL OF MEDICAL VIROLOGY

Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection

(2020) Jasvinder Singh Bhatti et al.   MOLECULAR NEUROBIOLOGY

The COVID-19 Effect on the Immune System and Mitochondrial Dynamics in Diabetes, Obesity, and Dementia

(2020) Katherine Holder et al.   NEUROSCIENTIST

Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future

(2020) Olayinka O. Ogunleye et al.   Frontiers in Pharmacology

Influenza virus polymerase inhibitors in clinical development

(2019) Frederick G. Hayden et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

(2017) Yousuke FURUTA et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient

(2017) Pierangelo Chinello et al.   PLoS Neglected Tropical Diseases

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

(2016) Vincent Madelain et al.   CLINICAL PHARMACOKINETICS

High dose favipiravir: first experience in a patient with Ebola

(2015) A.M. Borobia et al.   CLINICAL THERAPEUTICS